Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Long-term, Safety and Tolerability Study of SAR445088 in Participants With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088

NCT04802057 is registered in ClinicalTrials.gov with Bioverativ, a Sanofi company as lead sponsor.

NCT NCT04802057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04802057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Long-term, Safety and Tolerability Study of SAR445088 in Participants With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088
Lead sponsor
Bioverativ, a Sanofi company
Phase
Phase 1
Overall status
Terminated
Start date
March 22, 2021
Completion date
March 4, 2025
Enrollment
9 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune haemolytic anaemia